Plain English Summary
Background and study aims
Ovarian cancer is one of the most common cancers among women. Unfortunately, because early symptoms can be vague and somewhat similar to other conditions, it is often not diagnosed until it has reached an advanced stage and spread (metastasized) to other areas of the body. Surgery is useful in two ways; to remove tumors and to discover how far the cancer has spread (known as tumor staging). It is sometimes difficult to see all the tumors until surgery has begun and finding them all even during surgery can be a challenge, particularly when trying to find smaller ones. However, a new method, near-infrared fluorescent (NIRF) imaging has been developed that can see ovarian tumor tissue during surgery. In early studies it has been shown that ovarian cancer can be identified using NIRF imaging and a special dye called near-infrared fluorescent dye indocyanine green. This is because the dye tends to accumulate in tumors much more readily than they do in normal tissues (called the enhanced permeability and retention - or EPR - effect). We want to see how many tumors are seen using the new technique.
Who can participate?
Adult women aged at least 18 years either diagnosed with, or suspected to have, ovarian cancer and due for tumor staging or cytoreductive surgery (surgery to remove the tumor(s)) .
What does the study involve?
Ovarian cancer patients have indocyanine green given to them intravenously during surgery and NIRF performed to make the tumors easier to see. The number of tumors are then counted and a health professional (pathologist) then looks at the tumors that are removed to see how advanced the disease has become.
What are the possible benefits and risks of participating?
Possible benefits include finding more tumors that would otherwise be the case during surgery. A possible risk is an allergic reaction to indocyanine green. However, this is very rare (< 1 out of 20.000) and can be managed by the anaesthesiologist.
Where is the study run from?
Leiden University Medical Center (Netherlands)
When is the study starting and how long is it expected to run for?
October 2012 to October 2015
Who is funding the study?
Leiden University Medical Center (Netherlands)
Who is the main contact?
Dr Alexander Vahrmeijer
a.l.vahrmeijer@lumc.nl
Dr. Katja Gaarenstroom
k.n.gaarenstroom@lumc.nl
Study website
Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
P10.001
Study information
Scientific title
Intraoperative detection of ovarian cancer metastases using near-infrared fluorescence imaging and indocyanine green: a open-label, exploratory, non-randomised clinical trial
Acronym
GREENLIGHT
Study hypothesis
Near-infrared fluorescence imaging using indocyanine green can assist in the intraoperative detection of ovarian cancer metastases
Ethics approval(s)
Ethics Committee of the Leiden University Medical Center, 27/07/2012, ref: P10.001/NV/nv
Study design
Open-label exploratory non-randomised clinical trial
Primary study design
Interventional
Secondary study design
Non randomised study
Study setting(s)
Hospital
Study type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Ovarian cancer
Intervention
Intravenous administration of 20 mg Indocyanine Green
Intervention type
Other
Primary outcome measure
The number of intraoperative detected metastases using near-infrared fluorescence imaging and indocyanine green.This will be measured during surgery. When new anatomical sites are exposed during surgery, color images and NIR fluorescent images are obtained. After surgery, the Pathologist will perform histological assessment of the resected lesions for tumor status.
Secondary outcome measures
1. Sensitivity and specificity of detected fluorescent hotspots
2. Concordance between fluorescence signal and pathology assessment
Sensitivity and specificity of the fluorescent signal will be calculated after tumor status of theresected lesions is assessed. Concordance will also be calculated after surgery with theobtained information on fluorescence signal and tumor status of the resected lesions.
Overall study start date
01/10/2012
Overall study end date
01/10/2015
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. All patients diagnosed with or suspected for ovarian cancer planned for staging or cytoreductive surgery
2. Age >18 years old
Participant type(s)
Patient
Age group
Adult
Lower age limit
18 Years
Sex
Female
Target number of participants
15
Participant exclusion criteria
1. Renal impairment (defined as eGFR<55)
2. History of allergy to iodine, shellfish or indocyanine green
3. Patient pregnant or lactating
Recruitment start date
01/10/2012
Recruitment end date
01/10/2015
Locations
Countries of recruitment
Netherlands
Study participating centre
Albinusdreef 2
Leiden
2333 ZA
Netherlands
Sponsor information
Organisation
Leiden University Medical Center (Netherlands)
Sponsor details
Albinusdreef 2
Leiden
2333 ZA
Netherlands
Sponsor type
Hospital/treatment centre
Website
ROR
Funders
Funder type
Hospital/treatment centre
Funder name
Leiden University Medical Center (Netherlands)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Individual participant data (IPD) sharing plan
IPD sharing plan summary
Not provided at time of registration
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 25/06/2015 | Yes | No |